<DOC>
	<DOCNO>NCT02113813</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ASP8273 determine maximum tolerate dose ( MTD ) and/or recommend Phase 2 dose ( RP2D ) . This study also determine pharmacokinetics ( PK ) ASP8273 , evaluate potential inhibition CYP3A4 ASP8273 antitumor activity ASP8273 well determine effect food bioavailability ASP8273 .</brief_summary>
	<brief_title>A Dose Escalation Study ASP8273 Subjects With Non-Small-Cell Lung Cancer ( NSCLC ) Who Have Epidermal Growth Factor Receptor ( EGFR ) Mutations</brief_title>
	<detailed_description>This study compose 2 part : part 1 dose escalation phase part 2 recommend Phase 2 dose ( RP2D ) phase , Food Effect ( FE ) cohort Exon 20 cohort .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Nonchild bear potential able follow birth control requirement Eastern Cooperative Oncology Group ( ECOG ) ≤ 1 Life expectancy ≥ 12 week Laboratory criterion : Neutrophil count ≥ 1,500/mm3 Platelet count ≥ 7.5 x 104 /mm3 Hemoglobin ≥ 9.0 g/dL Lymphocyte count ≥ 500/mm3 Serum creatinine &lt; 1.5 x institutional Upper Limit Normal ( ULN ) estimate glomerular filtration rate ( eGFR ) &gt; 50 ml/min calculate Modification Diet Renal Disease ( MDRD ) equation Total bilirubin &lt; 1.5 x ULN ( except subject document Gilbert 's syndrome ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3.0 x ULN Dose escalation subject : Epidermal Growth Factor Receptor ( EGFR ) activate mutation local testing : exon 18 G719X , exon 19 deletion , exon 21 L861Q , exon 21 L858R exon 20 insertion ; receive prior treatment EGFR Tyrosine Kinase Inhibitor ( TKI ) Response expansion/RP2D expansion/ FE Cohort subject : disease progression intolerant prior EGFR TKI ; activate mutation AND T790M mutation ; tumor sample subsequent EGFR TKI available central testing ; least one measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Inclusion Criteria Exon 20 cohort : Subject line treatment EGFR exon 20 insertion mutation examination NSCLC tissue cellular specimen . Local testing may determine eligibility tumor sample also send central testing . Subjects must least 1 measurable lesion base RECIST version 1.1 . Any ongoing toxicity ≥ Grade 2 attributable prior NonSmallCell Lung Cancer ( NSCLC ) treatment Prior EGFR inhibitor within 6 day ; receive prior treatment agent antitumor activity chemotherapy , radiotherapy , immunotherapy within 14 day ; investigational therapy within 28 day 5 halflives , whichever short ; blood transfusion hemopoietic factor within 14 day ; major surgery within 14 day ; strong CYP3A4 inhibitor within 7 day Positive hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( antiHCV ) Human Immunodeficiency Virus ( HIV ) Symptomatic Central Nervous System ( CNS ) metastasis Active infection require systemic therapy within 14 day Severe uncontrolled systemic disease include uncontrolled hypertension History active interstitial lung disease Screening QTcF &gt; 450 msec current medication know prolong QT ≥ Grade 2 cardiac arrhythmia uncontrolled atrial fib grade ; Class 3 4 New York Heart Association congestive heart failure ; history severe/unstable angina , myocardial infarction cerebrovascular accident within 6 month History gastrointestinal ulcer bleed within 3 month ; digestive tract dysfunction Concurrent corneal disorder ophthalmologic condition make subject unsuitable RP2D cohort subject : contraindication midazolam , midazolam within 7 day , medication supplement know strong CYP3A inhibitor within 7 day inducer within 12 day Any malignancy require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>irreversible EGFR inhibitor</keyword>
	<keyword>Non-Small-Cell Lung Cancer</keyword>
	<keyword>Midazolam</keyword>
	<keyword>T790M resistance mutation</keyword>
	<keyword>EGFR</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Epidermal Growth Factor Receptor mutation</keyword>
	<keyword>ASP8273</keyword>
</DOC>